Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application

Abstract

Ocular drug delivery has been a major challenge for clinical pharmacologists and biomaterial scientists due to intricate and unique anatomical and physiological barriers in the eye. The critical requirement varies from anterior and posterior ocular segments from a drug delivery perspective. Recently, many new drugs with special formulations have been introduced for targeted delivery with modified methods and routes of drug administration to improve drug delivery efficacy. Current developments in nanoformulations of drug carrier systems have become a promising attribute to enhance drug retention/permeation and prolong drug release in ocular tissue. Biodegradable polymers have been explored as the base polymers to prepare nanocarriers for encasing existing drugs to enhance the therapeutic effect with better tissue adherence, prolonged drug action, improved bioavailability, decreased toxicity, and targeted delivery in eye. In this review, we summarized recent studies on sustained ocular drug/gene delivery and emphasized on the nanocarriers made by biodegradable polymers such as liposome, poly lactic-co-glycolic acid (PLGA), chitosan, and gelatin. Moreover, we discussed the bio-distribution of these nanocarriers in the ocular tissue and their therapeutic applications in various ocular diseases.

References 83

1. 1.

   World Health Organization. Blindness and Vision Impairment Prevention.

   Not in our library

2. 2.

   Kels B.D., Grzybowski A., Grant-Kels J.M. Human ocular anatomy. Clin. Dermatol. 2015;33:140-146.

   Not in our library10.1016/j.clindermatol.2014.10.006

3. 3.

   Kolb H. Simple Anatomy of the Retina by Helga Kolb. 2011.

   Not in our library

4. 4.

   Barar J., Asadi M., Mortazavi-Tabatabaei S.A., Omidi Y. Ocular drug delivery; impact of in vitro cell culture models. J. Ophthalmic Vis. Res. 2009;4:238-252.

   Not in our library

5. 5.

   Kiel J.W. The ocular circulation. Colloquium Series on Integrated Systems Physiology: From Molecule to Function. 2011;1-81.

   Not in our library

6. 6.

   Kim Y.C., Chiang B., Wu X., Prausnitz M.R. Ocular delivery of macromolecules. J. Control. Release. 2014;190:172-181.

   Not in our library10.1016/j.jconrel.2014.06.043

7. 7.

   Shintani K., Shechtman D.L., Gurwood A.S. Review and update: Current treatment trends for patients with retinitis pigmentosa. Optometry. 2009;80:384-401.

   Not in our library10.1016/j.optm.2008.01.026

8. 8.

   Del Amo E.M., Urtti A. Current and future ophthalmic drug delivery systems: A shift to the posterior segment. Drug Discov. Today. 2008;13:135-143.

   Not in our library10.1016/j.drudis.2007.11.002

9. 9.

   Sampat K.M., Garg S.J. Complications of intravitreal injections. Curr. Opin. Ophthalmol. 2010;21:178-183.

   Not in our library10.1097/icu.0b013e328338679a

10. 10.

    Jager R.D., Aiello L.P., Patel S.C., Cunningham E.T. Risks of intravitreous injection: A comprehensive review. Retina. 2004;24:676-698.

    Not in our library10.1097/00006982-200410000-00002

11. 11.

    Gerstenblith A.T., Rabinowitz M.P. The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease. 2012.

    Not in our library

12. 12.

    Gaudana R., Jwala J., Boddu S.H., Mitra A.K. Recent perspectives in ocular drug delivery. Pharm. Res. 2009;26:1197.

    Not in our library10.1007/s11095-008-9694-0

13. 13.

    Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 2006;58:1131-1135.

    Not in our library10.1016/j.addr.2006.07.027

14. 14.

    Chang C.Y., Wang M.C., Miyagawa T., Chen Z.Y., Lin F.H., Chen K.H., Liu G.S., Tseng C.L. Preparation of arginine–glycine–aspartic acid-modified biopolymeric nanoparticles containing epigalloccatechin-3-gallate for targeting vascular endothelial cells to inhibit corneal neovascularization. Int. J. Nanomed. 2017;12:279-294.

    Not in our library10.2147/ijn.s114754

15. 15.

    Ali M., Byrne M.E. Challenges and solutions in topical ocular drug-delivery systems. Expert Rev. Clin. Pharmacol. 2008;1:145-161.

    Not in our library10.1586/17512433.1.1.145

16. 16.

    Tangri P., Khurana S. Basics of ocular drug delivery systems. Int. J. Res. Pharm. 2011;2:1541-1552.

    Not in our library

17. 17.

    Molokhia S.A., Thomas S.C., Garff K.J., Mandell K.J., Wirostko B.M. Anterior eye segment drug delivery systems: Current treatments and future challenges. J. Ocul. Pharmacol. Ther. 2013;29:92-105.

    Not in our library10.1089/jop.2012.0241

18. 18.

    Kuno N., Fujii S. Recent advances in ocular drug delivery systems. Polymers. 2011;3:193-221.

    Not in our library10.3390/polym3010193

19. 19.

    Shivhare R., Pathak A., Shrivastava N., Singh C., Tiwari G., Goyal R. An update review on novel advanced ocular drug delivery system. World J. Pharm. Pharm. Sci. 2012;1:545-568.

    Not in our library

20. 20.

    Tomi M., Hosoya K.-I. The role of blood–ocular barrier transporters in retinal drug disposition: An overview. Expert Opin. Drug Metab. Toxicol. 2010;6:1111-1124.

    Not in our library10.1517/17425255.2010.486401

21. 21.

    Souto E.B., Doktorovova S., Gonzalez-Mira E., Egea M.A., Garcia M.L. Feasibility of lipid nanoparticles for ocular delivery of anti-inflammatory drugs. Curr. Eye Res. 2010;35:537-552.

    Not in our library10.3109/02713681003760168

22. 22.

    Holekamp N.M. The vitreous gel: More than meets the eye. Am. J. Ophthalmol. 2010;149:32-36.

    Not in our library10.1016/j.ajo.2009.07.036

23. 23.

    Thakur S.S., Barnett N.L., Donaldson M.J., Parekh H.S. Intravitreal drug delivery in retinal disease: Are we out of our depth? Expert Opin. Drug Deliv. 2014;11:1575-1590.

    Not in our library10.1517/17425247.2014.927864

24. 24.

    Achouri D., Alhanout K., Piccerelle P., Andrieu V. Recent advances in ocular drug delivery. Drug Dev. Ind. Pharm. 2013;39:1599-1617.

    Not in our library10.3109/03639045.2012.736515

25. 25.

    Gaudana R., Ananthula H.K., Parenky A., Mitra A.K. Ocular drug delivery. AAPS J. 2010;12:348-360.

    Not in our library10.1208/s12248-010-9183-3

26. 26.

    HS Boddu S., Gupta H., Patel S. Drug delivery to the back of the eye following topical administration: An update on research and patenting activity. Recent Pat. Drug Deliv. Formul. 2014;8:27-36.

    Not in our library10.2174/1872211308666140130093301

27. 27.

    Hikichi T., Kado M., Yoshida A. Intravitreal injection of hyaluronidase cannot induce posterior vitreous detachment in the rabbit. Retina. 2000;20:195-198.

    Not in our library10.1097/00006982-200002000-00014

28. 28.

    Martens T.F., Remaut K., Deschout H., Engbersen J.F., Hennink W.E., Van Steenbergen M.J., Demeester J., De Smedt S.C., Braeckmans K. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J. Control Release. 2015;202:83-92.

    Not in our library10.1016/j.jconrel.2015.01.030

29. 29.

    Sahoo S.K., Dilnawaz F., Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov. Today. 2008;13:144-151.

    Not in our library10.1016/j.drudis.2007.10.021

30. 30.

    Nagarwal R.C., Kant S., Singh P.N., Maiti P., Pandit J.K. Polymeric nanoparticulate system: A potential appproach for ocular drug delivery. J. Control. Release. 2009;136:2-13.

    Not in our library10.1016/j.jconrel.2008.12.018

31. 31.

    Liu S., Jones L., Gu F.X. Nanomaterials for ocular drug delivery. Macromol. Biosci. 2012;12:608-620.

    Not in our library10.1002/mabi.201100419

32. 32.

    Ali Y., Lehmussaari K. Industrial perspective in ocular drug delivery. Adv. Drug Deliv. Rev. 2006;57:1258-1268.

    Not in our library10.1016/j.addr.2006.07.022

33. 33.

    Zhang Q., Li J., Gao W., Zhang L. Nanoparticles for Ocular Drug Delivery. Ophthalmic Disease Mechanisms and Drug Discovery. 2017;197-223.

    Not in our library

34. 34.
    Ocular Drug Delivery Barriers—Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases · 2018

    No notice
35. 35.

    Chen H., Jin Y., Sun L., Li X., Nan K., Liu H., Zheng Q., Wang B. Recent Developments in Ophthalmic Drug Delivery Systems for Therapy of Both Anterior and Posterior Segment Diseases. Colloids Interface Sci. Commun. 2018;24:54-61.

    Not in our library10.1016/j.colcom.2018.03.008

36. 36.

    Reimondez-Troitiño S., Csaba N., Alonso M.J., de la Fuente M. Nanotherapies for the treatment of ocular diseases. Eur. J. Pharm. Biopharm. 2015;95:279-293.

    Not in our library10.1016/j.ejpb.2015.02.019

37. 37.

    Akhter S., Anwar M., Siddiqui M.A., Ahmad I., Ahmad J., Ahmad M.Z., Bhatnagar A., Ahmad F.J. Improving the topical ocular pharmacokinetics of an immunosuppressant agent with mucoadhesive nanoemulsions: Formulation development, in-vitro and in-vivo studies. Colloids Surf. B Biointerfaces. 2016;148:19-29.

    Not in our library10.1016/j.colsurfb.2016.08.048

38. 38.

    Tseng C.L., Chen K.H., Su W.Y., Lee Y.H., Wu C.C., Lin F.H. Cationic Gelatin Nanoparticles for Drug Delivery to the Ocular Surface: In vitro and In vivo Evaluation. J. Nanomater. 2013;2013:1-11.

    Not in our library

39. 39.

    Xu Q., Boylan N.J., Suk J.S., Wang Y.-Y., Nance E.A., Yang J.-C., McDonnell P.J., Cone R.A., Duh E.J., Hanes J. Nanoparticle diffusion in, and microrheology of, the bovine vitreous ex vivo. J. Control. Release. 2013;167:76-84.

    Not in our library10.1016/j.jconrel.2013.01.018

40. 40.

    Ying L., Tahara K., Takeuchi H. Drug delivery to the ocular posterior segment using lipid emulsion via eye drop administration: Effect of emulsion formulations and surface modification. Int. J. Pharm. 2013;453:329-335.

    Not in our library10.1016/j.ijpharm.2013.06.024

Cited by papers we hold 4

• Nanotechnology-based ocular drug delivery systems: recent advances and future prospects · 2023
  No notice
• Considerations for Polymers Used in Ocular Drug Delivery · 2022
  Not checked
• PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases · 2022
  No notice
• Biopolymer: A Sustainable Material for Food and Medical Applications · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.